Orexo AB (publ) – OTC:ORXOY
Orexo AB (publ) stock price today
Orexo AB (publ) stock price monthly change
Orexo AB (publ) stock price quarterly change
Orexo AB (publ) stock price yearly change
Orexo AB (publ) key metrics
Market Cap | 59.69M |
Enterprise value | 479.05M |
P/E | -3.46 |
EV/Sales | 0.78 |
EV/EBITDA | -8.11 |
Price/Sales | 0.84 |
Price/Book | 1.72 |
PEG ratio | -0.26 |
EPS | -2.14 |
Revenue | 619.1M |
EBITDA | 27.7M |
Income | -73.4M |
Revenue Q/Q | -12.27% |
Revenue Y/Y | -0.72% |
Profit margin | -24.8% |
Oper. margin | -28.88% |
Gross margin | 84.14% |
EBIT margin | -28.88% |
EBITDA margin | 4.47% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOrexo AB (publ) stock price history
Orexo AB (publ) stock forecast
Orexo AB (publ) financial statements
| Jun 2023 | 157.7M | -12.6M | -7.99% |
|---|---|---|---|
| Sep 2023 | 156.1M | -33.3M | -21.33% |
| Dec 2023 | 166M | -18.6M | -11.2% |
| Mar 2024 | 139.3M | -8.9M | -6.39% |
| Jun 2023 | 926900000 | 803.1M | 86.64% |
|---|---|---|---|
| Sep 2023 | 869000000 | 777M | 89.41% |
| Dec 2023 | 786600000 | 727.7M | 92.51% |
| Mar 2024 | 829900000 | 768.5M | 92.6% |
| Jun 2023 | -12.7M | 125.1M | -14M |
|---|---|---|---|
| Sep 2023 | -21.9M | -6.6M | -39.1M |
| Dec 2023 | -2.6M | -900K | -5.5M |
| Mar 2024 | -18.9M | -1.2M | 43.3M |
Orexo AB (publ) alternative data
| Aug 2023 | 126 |
|---|---|
| Sep 2023 | 120 |
| Oct 2023 | 120 |
| Nov 2023 | 120 |
| Dec 2023 | 118 |
| Jan 2024 | 118 |
| Feb 2024 | 118 |
| Mar 2024 | 116 |
| Apr 2024 | 116 |
| May 2024 | 116 |
| Jun 2024 | 116 |
| Jul 2024 | 113 |
Orexo AB (publ) other data
Tuesday, 17 December 2024 | ||
| Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | prnewswire.com | |
Friday, 25 October 2024 | ||
| Orexo initiates new study of OX640 in participants with allergic rhinitis | prnewswire.com | |
Friday, 4 October 2024 | ||
| Orexo´s Nomination Committee for the Annual General Meeting 2025 | prnewswire.com | |
Tuesday, 3 September 2024 | ||
| Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024 | prnewswire.com | |
Tuesday, 16 July 2024 | ||
| Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | prnewswire.com | |
Wednesday, 10 July 2024 | ||
| Orexo AB´s sustainability work ranked among top 5% by EcoVadis | prnewswire.com | |
Monday, 8 July 2024 | ||
| Orexo: invitation to presentation of the Q2 2024 Interim Report | prnewswire.com | |
Friday, 10 May 2024 | ||
| Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | prnewswire.com |
-
What's the price of Orexo AB (publ) stock today?
One share of Orexo AB (publ) stock can currently be purchased for approximately $1.91.
-
When is Orexo AB (publ)'s next earnings date?
Unfortunately, Orexo AB (publ)'s (ORXOY) next earnings date is currently unknown.
-
Does Orexo AB (publ) pay dividends?
No, Orexo AB (publ) does not pay dividends.
-
How much money does Orexo AB (publ) make?
Orexo AB (publ) has a market capitalization of 59.69M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.32% to 638.8M US dollars.
-
What is Orexo AB (publ)'s stock symbol?
Orexo AB (publ) is traded on the OTC under the ticker symbol "ORXOY".
-
What is Orexo AB (publ)'s primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of Orexo AB (publ)?
Shares of Orexo AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Orexo AB (publ) have?
As Jul 2024, Orexo AB (publ) employs 113 workers, which is 3% less then previous month and 3% less then previous quarter.
-
When Orexo AB (publ) went public?
Orexo AB (publ) is publicly traded company for more then 12 years since IPO on 9 Sep 2013.
-
What is Orexo AB (publ)'s official website?
The official website for Orexo AB (publ) is orexo.com.
-
How can i contact Orexo AB (publ)?
Orexo AB (publ) can be reached via phone at +46 18 780 88 00.
Orexo AB (publ) company profile:
Orexo AB (publ)
orexo.comOTC
126
Drug Manufacturers—Specialty & Generic
Healthcare
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Uppsala, 751 05
:
ISIN: US68616W1027
:
